Tweet
Krka UK’s parent company, The Krka Group also reported a strong performance in 2020, with revenue climbing 3% to €1,534.9 million and net profit of €288.9 million, an 18% rise compared to 2019.
Commenting on Krka UK’s performance during 2020, Krka UK General Manager Ned Flaxman said: “We believe our rapid growth can be attributed to our resolute focus on minimising costs in order to maximise the value that our high-quality generic products can deliver to practice profitability, making us the smart alternative for many of our customers.
“I am really proud of the way our team has supported our customers through the challenges of the last 12 months. I am also delighted with the positive customer response to the four new products we launched during lockdown: Prinocate, a broad spectrum parasiticide for cats and dogs; Flimabend Smallholder, a water-based worming treatment in a pack size to suit the needs of domestic poultry owners; Ataxxa flea and tick spot-on for dogs and our BRD treatment, Tuloxxin.”
He continued: “As you’d expect, many of us have been working from home for some time and we expect to see flexible working continue as we emerge into the ‘new normal’. However, we are also strong believers in the power of teamwork and there is nothing like being together in the same office to achieve this alignment and customer focus.
“Our new, more spacious offices will enable us to expand our customer support team and to enjoy working together again once it is safe to do so.”